We are currently updating the database - data may be missing for the next 10 minutes. We apologize for any inconvenience.
Human Metabolome Database Version 2.5
Showing metabocard for 12-Keto-leukotriene B4 (HMDB04234)
Legend: enzyme field
| Version | 2.5 | ||||||||||||||||||
| Creation Date | 2006-08-13 15:56:58 | ||||||||||||||||||
| Update Date | 2009-05-05 20:59:55 | ||||||||||||||||||
| Accession Number | HMDB04234 | ||||||||||||||||||
| Secondary Accession Numbers | HMDB05086 | ||||||||||||||||||
| Common Name | 12-Keto-leukotriene B4 | ||||||||||||||||||
| Description | 12-Keto-leukotriene B4 is formed when leukotriene B4 (LTB4) is metabolized by beta-oxidation. LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 8632343, 9667737) Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes) and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signaling pathways. | ||||||||||||||||||
| Synonyms |
|
||||||||||||||||||
| Chemical IUPAC Name | (5S,6Z,8E,10E,14Z)-5-hydroxy-12-oxoicosa-6,8,10,14-tetraenoic acid | ||||||||||||||||||
| Chemical Formula | C20H30O4 | ||||||||||||||||||
| Chemical Structure |  |
||||||||||||||||||
| Chemical Taxonomy |
|
||||||||||||||||||
| Average Molecular Weight | 334.450 | ||||||||||||||||||
| Monoisotopic Molecular Weight | 334.214417 | ||||||||||||||||||
| Isomeric SMILES | CCCCCC=C/CC(=O)C=CC=CC=C/[C@@H](O)CCCC(O)=O | ||||||||||||||||||
| Canonical SMILES | CCCCCC=CCC(=O)C=CC=CC=CC(O)CCCC(O)=O | ||||||||||||||||||
| KEGG Compound ID | C05949  |
||||||||||||||||||
| BioCyc ID | Not Available | ||||||||||||||||||
| BiGG ID | Not Available | ||||||||||||||||||
| Wikipedia Link | Not Available | ||||||||||||||||||
| NuGOwiki Link | HMDB04234 |
||||||||||||||||||
| Metagene Link | HMDB04234 |
||||||||||||||||||
| METLIN ID | Not Available | ||||||||||||||||||
| PubChem Compound | 5280876 |
||||||||||||||||||
| PubChem Substance | 15952391 |
||||||||||||||||||
| ChEBI ID | 27814 |
||||||||||||||||||
| CAS Registry Number | 136696-10-1 | ||||||||||||||||||
| InChI Identifier | InChI=1/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,19,22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t19-/m1/s1 | ||||||||||||||||||
| Synthesis Reference | Not Available | ||||||||||||||||||
| Melting Point (Experimental) | Not Available | ||||||||||||||||||
| Experimental Water Solubility | Not Available Source: PhysProp | ||||||||||||||||||
| Predicted Water Solubility | 7.74e-03 mg/mL [Predicted by ALOGPS] Calculated using ALOGPS | ||||||||||||||||||
| Physiological Charge | -1 | ||||||||||||||||||
| State | Solid | ||||||||||||||||||
| Experimental LogP/Hydrophobicity | 3.884 Source: PhysProp | ||||||||||||||||||
| Predicted LogP/Hydrophobicity | 4.4 [Predicted by PubChem via XLOGP]; 4.67 [Predicted by ALOGPS] Calculated using ALOGPS | ||||||||||||||||||
| Material Safety Data Sheet (MSDS) | Not Available | ||||||||||||||||||
| MOL File | Show |
||||||||||||||||||
| SDF File | Show |
||||||||||||||||||
| PDB File | Show |
||||||||||||||||||
| 2D Structure | |||||||||||||||||||
| 3D Structure | |||||||||||||||||||
| Experimental PDB ID | Not Available | ||||||||||||||||||
| Experimental 1H NMR Spectrum | Not Available | ||||||||||||||||||
| Experimental 13C NMR Spectrum | Not Available | ||||||||||||||||||
| Experimental 13C HSQC Spectrum | Not Available | ||||||||||||||||||
| Predicted 1H NMR Spectrum |
Show Image Show Peaklist |
||||||||||||||||||
| Predicted 13C NMR Spectrum |
Show Image Show Peaklist |
||||||||||||||||||
| Mass Spectrum | Not Available | ||||||||||||||||||
| Simplified TOCSY Spectrum | Not Available | ||||||||||||||||||
| BMRB Spectrum | Not Available | ||||||||||||||||||
| Cellular Location | Not Available | ||||||||||||||||||
| Biofluid Location | Not Available | ||||||||||||||||||
| Tissue Location | Not Available | ||||||||||||||||||
| Concentrations (Normal) | Not Available | ||||||||||||||||||
| Concentrations (Abnormal) | Not Available | ||||||||||||||||||
| Associated Disorders | Not Available | ||||||||||||||||||
| OMIM ID | Not Available | ||||||||||||||||||
| Pathways |
|
||||||||||||||||||
| General References |
|
